The RSI Oscillator for CGON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 12 similar instances when the indicator left oversold territory. In 11 of the 12 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 25 of 26 cases where CGON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 24 of 29 cases over the following month. The odds of a continued upward trend are 83%.
Following a +0.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 118 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In 37 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
CGON moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGON crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for CGON entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.387) is normal, around the industry mean (2.973). P/E Ratio (-23.249) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Oscillator for ORKA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 21 of the 25 cases the stock moved higher. This puts the odds of a move higher at 84%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ORKA as a result. In 69 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ORKA just turned positive on October 21, 2026. Looking at past instances where ORKA's MACD turned positive, the stock continued to rise in 40 of 54 cases over the following month. The odds of a continued upward trend are 74%.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORKA advanced for three days, in 203 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ORKA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
ORKA moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORKA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for ORKA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.833) is normal, around the industry mean (2.973). P/E Ratio (-39.779) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ORKA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORKA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ORKA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 94 | |
PRICE GROWTH RATING 1..100 | 39 | |
P/E GROWTH RATING 1..100 | 27 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CGON | ORKA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 72% |
| Advances ODDS (%) | 2 days ago 81% | 2 days ago 78% |
| Declines ODDS (%) | 10 days ago 77% | 8 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 59% |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 75% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGON’s FA Score shows that 2 FA rating(s) are green while ORKA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGON’s TA Score shows that 5 TA indicator(s) are bullish while ORKA’s TA Score has 5 bullish TA indicator(s).
CGON (@Biotechnology) experienced а +1.10% price change this week, while ORKA (@Biotechnology) price change was +9.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.37%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -16.53%.
CGON is expected to report earnings on Nov 13, 2026.
ORKA is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CGON has been loosely correlated with MLTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then MLTX could also see price increases.
| Ticker / NAME | Correlation To CGON | 1D Price Change % | ||
|---|---|---|---|---|
| CGON | 100% | +0.48% | ||
| MLTX - CGON | 50% Loosely correlated | +15.87% | ||
| BCAX - CGON | 43% Loosely correlated | -1.68% | ||
| IDYA - CGON | 43% Loosely correlated | +1.83% | ||
| SRRK - CGON | 43% Loosely correlated | -2.42% | ||
| ORKA - CGON | 42% Loosely correlated | +1.54% | ||
More | ||||
A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To ORKA | 1D Price Change % | ||
|---|---|---|---|---|
| ORKA | 100% | +1.54% | ||
| SYRE - ORKA | 51% Loosely correlated | -0.67% | ||
| XNCR - ORKA | 45% Loosely correlated | +2.70% | ||
| DNTH - ORKA | 43% Loosely correlated | +0.55% | ||
| JBIO - ORKA | 42% Loosely correlated | -1.45% | ||
| TRVI - ORKA | 41% Loosely correlated | +1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AKRE | 60.39 | 2.26 | +3.89% |
| Akre Focus ETF (AKRE) | |||
| TDSB | 24.80 | -0.01 | -0.04% |
| ETC Cabana Target Beta ETF (TDSB) | |||
| NBCM | 31.46 | -0.06 | -0.19% |
| Neuberger Commodity Strategy ETF (NBCM) | |||
| GRX | 10.02 | -0.06 | -0.60% |
| Gabelli Healthcare & Wellness Trust (The) | |||
| GASZ | 20.19 | -0.96 | -4.53% |
| Corgi Natural Gas Power & Turbines ETF (GASZ) | |||